Wang W - Search Results

1

mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.

Wang W, Bai W, Wang E, Zhao Y, Liu L, Yang M, Cai H, Xia D, Zhang L, Niu J, Yin Z, Zhang Z, Fan D, Xia J, Han G. Wang W, et al. Among authors: wang e. Int J Cancer. 2017 Jan 15;140(2):390-399. doi: 10.1002/ijc.30451. Epub 2016 Oct 17. Int J Cancer. 2017. PMID: 27681592

2

Response assessment for HCC patients treated with repeated TACE: The optimal time-point is still an open issue.

Wang W, Zhao Y, Bai W, Han G. Wang W, et al. J Hepatol. 2015 Dec;63(6):1530-1. doi: 10.1016/j.jhep.2015.07.031. Epub 2015 Aug 6. J Hepatol. 2015. PMID: 26256436 No abstract available.

3

Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.

Zhao Y, Li H, Bai W, Liu J, Lv W, Sahu S, Guan S, Qin X, Wang W, Ren W, Mu W, Guo W, Gu S, Ma Y, Yin Z, Guo W, Wang W, Wang Y, Duran R, Fan D, Zhang Z, Han G. Zhao Y, et al. Among authors: wang w, wang y. Int J Cancer. 2016 Aug 15;139(4):928-37. doi: 10.1002/ijc.30124. Int J Cancer. 2016. PMID: 27038145

4

Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.

Wang W, Lie P, Guo M, He J. Wang W, et al. Int J Cancer. 2017 Sep 1;141(5):1018-1028. doi: 10.1002/ijc.30678. Epub 2017 Jun 20. Int J Cancer. 2017. PMID: 28263392 Review.

5

Chemoembolization for Hepatocellular Carcinoma in Patients with Extrahepatic Spread: Prognostic Determinants and Appropriate Candidates.

Wang E, Liu L, Xia D, Wang W, Bai W, Wang Q, Yuan J, Li X, Zhang L, Niu J, Yin Z, Xia J, Cai H, Fan D, Han G. Wang E, et al. Among authors: wang w, wang q. J Vasc Interv Radiol. 2017 Jul;28(7):956-962. doi: 10.1016/j.jvir.2017.02.016. Epub 2017 Apr 15. J Vasc Interv Radiol. 2017. PMID: 28420555

6

Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?

Zhao Y, Duran R, Bai W, Sahu S, Wang W, Kabus S, Lin M, Han G, Geschwind JF. Zhao Y, et al. Among authors: wang w. Cardiovasc Intervent Radiol. 2018 Mar;41(3):433-442. doi: 10.1007/s00270-017-1829-4. Epub 2017 Oct 30. Cardiovasc Intervent Radiol. 2018. PMID: 29086058 Free PMC article.

7

Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC.

Wang E, Xia D, Bai W, Wang Z, Wang Q, Liu L, Wang W, Yuan J, Li X, Chen H, Lv Y, Niu J, He C, Guo W, Yin Z, Luo B, Han N, Wang Z, Yu T, Yuan X, Li K, Tie J, Li C, Cai H, Xia J, Fan D, Han G. Wang E, et al. Among authors: wang w, wang z, wang q. Invest New Drugs. 2019 Jun;37(3):401-414. doi: 10.1007/s10637-018-0640-7. Epub 2018 Jul 18. Invest New Drugs. 2019. PMID: 30019101

8

Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study.

Wang Z, Wang E, Bai W, Xia D, Ding R, Li J, Wang Q, Liu L, Sun J, Mu W, Zhao H, Pan X, Shao G, Zhu X, Yin G, Shi H, Wu J, Lin Z, Yang S, Liu J, Wang W, Zhu X, Lv Y, Li J, Chen H, Wang W, Li K, Yuan X, Yu T, Yuan J, Li X, Niu J, Yin Z, Xia J, Fan D, Han G. Wang Z, et al. Among authors: wang w, wang e, wang q. Liver Cancer. 2020 Jun;9(3):308-325. doi: 10.1159/000505692. Epub 2020 Feb 19. Liver Cancer. 2020. PMID: 32647633 Free PMC article.

9

Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization.

Xia D, Wang Q, Bai W, Wang E, Wang Z, Mu W, Sun J, Huang M, Yin G, Li H, Zhao H, Zhang C, Li J, Wu J, Zhu X, Yang S, Pan X, Li J, Li Z, Xu G, Shi H, Zhang H, Zhang Y, Ding R, Yu H, Zheng L, Yang X, Wang G, You N, Feng L, Zhang S, Huang W, Xu T, Fan W, Li X, Yang X, Zhou W, Wang W, Li X, Wang Z, Luo B, Niu J, Yuan J, Lv Y, Li K, Guo W, Yin Z, Fan D, Xia J, Han G; China HCC-TACE Study Group. Xia D, et al. Among authors: wang g, wang w, wang e, wang z, wang q. Eur Radiol. 2022 Sep;32(9):5799-5810. doi: 10.1007/s00330-022-08716-4. Epub 2022 Apr 6. Eur Radiol. 2022. PMID: 35381853

10

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

Jin ZC, Chen JJ, Zhu XL, Duan XH, Xin YJ, Zhong BY, Chen JZ, Tie J, Zhu KS, Zhang L, Huang M, Piao MJ, Li X, Shi HB, Liu RB, Xu AB, Ji F, Wu JB, Shao GL, Li HL, Huang MS, Peng ZY, Ji JS, Yuan CW, Liu XF, Hu ZC, Yang WZ, Yin GW, Huang JH, Ge NJ, Qi X, Zhao Y, Zhou JW, Xu GH, Tu Q, Lin HL, Zhang YJ, Jiang H, Shao HB, Su YJ, Chen TS, Shi BQ, Zhou X, Zhao HT, Zhu HD, Ren ZG, Teng GJ; CHANCE2201 Investigators. Jin ZC, et al. EClinicalMedicine. 2024 May 6;72:102622. doi: 10.1016/j.eclinm.2024.102622. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38745965 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88,803 results

Search Page

Filters